New combo pill shows promise for type 2 diabetes in japanese patients

NCT ID NCT00974090

Completed Disease control Sponsor: Tanabe Pharma Corporation Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether adding teneligliptin to standard sulfonylurea therapy improves blood sugar control in 194 Japanese adults with type 2 diabetes. Participants received either teneligliptin or a placebo for 12 weeks, followed by an open-label extension for up to 52 weeks. The main goal was to measure changes in HbA1c, a key marker of long-term blood sugar levels.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Teneligliptin (a DPP-4 inhibitor) combined with sulfonylurea
What this could lead to: If successful, this could provide a new combination option to help people with type 2 diabetes better control their blood sugar levels.
What could go wrong: This is a completed Phase 3 trial, but results may not apply to all populations. As with any diabetes medication, there are risks of low blood sugar and other side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Insulin Resistance type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES MELLITUS

Contacts and locations

Locations

Study site

Sapporo, Hokkaido, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.